BMO on Sarepta (SRPT): 'Long-Term Elevidys Data Support Uptake & Competitive Positioning'
Tweet Send to a Friend
BMO Capital analyst Kostas Biliouris reiterated an Outperform rating and $200.00 price target on Sarepta Therapeutics (NASDAQ: SRPT)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
